Latest Reimbursement News

Brazilian Critical Minerals has reported striking economics for its Ema rare earths project, including a US$1.47 billion post-tax NPV, 105% IRR and six-month payback. The company’s A$7.87 million FY2026 loss, December debt maturity, permitting requirements and unresolved Drake dispute leave the development case dependent on execution and further funding.

Karoon Energy has confirmed an electrical fault in the newly installed power cable serving Baúna’s SPS-92 well, deferring about 3,500 barrels of oil a day. The repair requires a rig-based intervention, prompting cuts to production guidance and higher unit cost forecasts for 2026.

St Barbara is positioning itself as a debt-free Nova Scotia gold developer after a proposed A$453 million Simberi exit, with a potential special dividend and share buy-back still on the table. Its updated 15-Mile study points to a larger reserve, longer mine life and stronger project economics, but those figures remain study-based and conditional on execution.

Lord Resources has extended copper mineralisation across multiple lodes at Ilgarari, but its FY2026 annual report carries a material uncertainty over whether the explorer can continue as a going concern. The company ended the year with $554,820 in cash after a $2.54 million loss and $1.87 million of operating cash outflows.

Bannerman Energy has completed CNOL’s US$320.4 million strategic investment in the Etango uranium project, giving the joint venture approximately US$303 million in cash and a debt-free construction pathway. The project now moves towards a Final Investment Decision and full-scale construction targeted for Q4 2026.

4DMedical delivered sharp growth in scans, sites and operating revenue as CT:VQ moved into commercial deployment across several global markets. But the company remains loss-making and its auditor issued a qualified opinion over the carrying value of goodwill and other intangible assets.

Bannerman Energy has moved its Etango uranium project materially closer to construction after completing a A$124 million placement and clearing conditions for its CNOL strategic investment. The project is advancing on site, but full-scale construction still depends on Final Investment Decision and completion of the joint venture documentation.

BCAL Diagnostics has begun introducing ClearNote Health’s Avantect Multi-Cancer blood test in Australia, starting with Sydney and Melbourne. The test reported 56.2% sensitivity and 98.4% specificity in a case-control validation study, but the company says a negative result does not rule out cancer.

Rhythm Biosciences has completed the first phase of transferring its ColoSTAT blood test to an independent NHS laboratory in England. The milestone supports its international laboratory-partnership strategy, but clinical validation and NHS adoption remain ahead.

CMS has finalised higher Medicare inpatient reimbursement for EBR Systems’ WiSE System, lifting base payment rates by up to 93% from 1 October 2026. The change improves the commercial payment pathway, although its financial impact will depend on procedure volumes, hospital adoption and NTAP eligibility.

LE Minerals has amended its proposed $20 million sale of three Queensland graphite projects after ASX flagged promoter and classified-asset rules that could lock up consideration shares. The cash component may now range from $2 million to $5 million, while shareholder approvals and MBM’s proposed IPO remain key execution hurdles.

Avenira has agreed to supply Hebang with 500,000 wet metric tonnes of Wonarah phosphate rock annually for four years, covering more than 80% of expected DSO production. The commercial opportunity is substantial, but pricing, approvals and project arrangements remain unresolved.